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Objective: To identify trajectories of sleep quality up to three years after breast cancer diagnosis and to
assess differences in characteristics of patients across distinct trajectories.
Methods: A total of 458 breast cancer patients underwent a neurological evaluation before treatment and
at one and three years after diagnosis. Clinical data were obtained throughout the follow-up. Anxiety and
depression were evaluated at baseline, using the Hospital Anxiety and Depression Scale. In all sessions of
follow-up, sleep quality was assessed using the Pittsburgh Sleep Quality Index. Model-based clustering
was used to identify groups of patients with homogeneous variation in sleep quality.
Results: We identiﬁed three trajectories of variation in sleep quality, named “low” (LSQ), “medium”
(MSQ), and “high sleep quality” (HSQ). Women in the HSQ trajectory presented good sleep quality during
the three years. LSQ and MSQ trajectories were characterized by poor sleep quality during the whole
period, although during the ﬁrst year the latter depicted a signiﬁcant deterioration of sleep quality and
the former a signiﬁcant improvement. Patients included in the LSQ trajectory were more likely to have
clinically signiﬁcant anxiety and depression at baseline. The two trajectories with worse sleep quality
were associated with neuropathic pain three years after cancer diagnosis.
Conclusions: This study provides a model for describing the variation in sleep quality during the ﬁrst
three years after breast cancer diagnosis, based on three main trajectories. Further studies are needed
understanding the heterogeneity of the individual trajectories within each of these major patterns of
variation.
© 2017 Elsevier B.V. All rights reserved.1. Introduction
Sleep disturbances are common among women with breast
cancer, being estimated to affect up to 65% of patients [1e4], which
is a greater proportion than observed in the general population
[5,6]. In addition to factors that increase the vulnerability to
develop sleep problems (eg, being female, older age, personal, and
familial history of insomnia, co-occurrence of another psychiatric
disorder) and to those that contribute to their maintenance over
time (eg, maladaptive sleep behaviours, faulty beliefs about
insomnia causes), stressful life events such as the diagnosis of anda Saúde Pública e Forenses e
de do Porto, Al. Prof Herna^nioncological disease or cancer treatments and their side-effects have
been reported to act as precipitating factors, which may trigger
development of sleep disturbance among cancer patients [7].
A systematic review assessing the impact of breast cancer
treatments on sleep disturbances, concluded that women submit-
ted to chemotherapy or radiotherapy reported higher levels of sleep
disturbances than those not undergoing these treatments; how-
ever, evidence from prospective studies evaluating patients before
and after treatment was scarce [8]. In fact, it has been noted that a
high proportion of women already presented higher levels of sleep
disturbance prior to treatments [9,10] whereas some other patients
with insomnia reported that it began months after diagnosis [11],
highlighting the need for a comprehensive evaluation of different
longitudinal patterns of sleep quality among women with breast
cancer.
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frequent during the ﬁrst year after cancer diagnosis [12], and affect
more than half of the women treated for breast cancer after three
years [13]. Although neuropathic pain (NP), chemotherapy-induced
peripheral neuropathy (CIPN) and cognitive impairment are among
the most frequently described side effects, there is scarce infor-
mation about their contribution to different trajectories of sleep
quality.
Therefore, the purpose of this study was to identify trajectories
of sleep quality during the ﬁrst three years after breast cancer
treatment and to assess differences in sociodemographic and
clinical characteristics of the patients across distinct trajectories of
sleep quality.
2. Material and methods
This study is part of a larger prospective cohort study assessing
neurological complications of breast cancer and its treatments among
womenwith newly diagnosed breast cancer, followed for three years.
The study protocol has been described in detail elsewhere [14].
2.1. Participants and setting
Participants were consecutively recruited in 2012, among those
proposed for surgery, aged 18 years or older, admitted to the Breast
Clinic of the Portuguese Institute of Oncology of Porto (IPO-Porto),
Portugal. Brieﬂy, we excluded those treated with chemotherapy
and/or radiotherapy in the chest or axillary areas for other primary
cancer, those that had received any treatment for breast cancer
before, and those with a high probability of cognitive impairment
[score lower than 17, or lower than 16 for women over 65 years, in
the Montreal Cognitive Assessment (MoCA) [15]]. A total of 506
participants were enrolled in the cohort and underwent a baseline
evaluation before treatment.
2.2. Procedures and measures
Participants were evaluated, including a neurological assess-
ment, at baseline (before any treatment) and at one and three years
after enrolment. The median time [percentile 25epercentile 75
(P25eP75)] between diagnosis (date of ﬁrst histological conﬁrma-
tion) and the baseline evaluation was 24 days (18e32).
At baseline, sociodemographic data were collected using a
structured questionnaire, and clinical records were reviewed for
cancer stage and menopausal status. Cancer stage was classiﬁed
according to the American Joint Committee on Cancer Staging
Manual [16]. When menopausal status was not speciﬁed, all
women older than 60 years, women who underwent a bilateral
ovariectomy and those with an intact uterus and being amenor-
rheic for at least one year prior to the diagnosis of breast cancer
were classiﬁed as postmenopausal, or otherwise as premeno-
pausal [17].
At one and three years after enrolment, clinical records were
examined for breast cancer treatments and the occurrence of
cancer relapse. In addition, the presence of neurological compli-
cations affecting the patients at one and/or three years after cancer
diagnosis, namely NP and CIPN was recorded. NP was considered
probable, according to the classiﬁcation system adopted by the
International Association for the Study of Pain, when pain distri-
butionwas neuroanatomically plausible and history was suggestive
of relevant lesions or diseases affecting the somatosensory system,
plus negative or positive sensory signs in neurological examination,
conﬁned to the innervation territory of the injury nervous structure
[18]. We considered NP as prevalent in each of the evaluations if it
was present in the last 24 h, in the breast, chest wall, axilla, ormedial upper arm on the affected side, donor region of breast
reconstruction, or in hands/feet (secondary to CIPN). CIPN was
deﬁned as peripheral neuropathy beginning after chemotherapy.
Among patients with preexisting peripheral neuropathy at base-
line, CIPN was considered to have occurred only if there was a
worsening of neuropathy after the beginning of chemotherapy.
Each patient was evaluated with MoCA (range: 0e30) at base-
line, and at one and three years. In each evaluation, cognitive
impairment was considered present, when the corresponding
MoCA score was at least 2.0 standard deviations below age- and
education-adjusted cut-offs for possible cognitive impairment [15].
The Hospital Anxiety and Depression Scale (HADS) [19] was
used to evaluate anxiety and depression at baseline. The HADS
consists of 14 items, with two seven-item subscales assessing
anxiety and depression in the past week (range: 0e21 for each
subscale); a score greater than or equal to 11 for each of them was
considered to be indicative of clinically signiﬁcant anxiety and/or
depression, as applicable [19].
The Pittsburgh Sleep Quality Index (PSQI) was used to evaluate
sleep quality at baseline, and at one and three years [20]. The PSQI
includes 19 items measuring seven components, including sub-
jective sleep quality, sleep latency, sleep duration, habitual sleep
efﬁciency, sleep disturbances, use of sleep medication and daytime
dysfunction. Components (range: 0e3) are summed to provide a
global score designed to measured sleep quality over the past
month (range: 0e21); a score greater than ﬁve indicates poor sleep
quality [20].
2.3. Statistical analysis
From the 506 participants who underwent a baseline evalua-
tion, 31 were lost to follow-up until the third year (11 patients died,
10 abandoned the study, six could not be contacted, two were
transferred to another hospital and two were considered unable to
cooperate by the neurologist). For the purposes of this study, we
excluded those with cancer stage IV at baseline (N ¼ 3), patients
with cancer relapse until the third year of follow-up (N ¼ 12) and
those with missing information on sleep quality (N ¼ 2). Therefore,
a total of 458 participants were included in the present analysis.
The patients not included (N ¼ 48) were not signiﬁcantly different
(participants included vs. participants not included) regarding age
(<55 years: 52.8% vs. 52.1%; P ¼ 0.921), education (4 years: 42.6%
vs. 43.5%; P ¼ 0.968) and presence of anxiety (39.0% vs. 29.2%;
P ¼ 0.184), depression (7.9% vs. 10.4%; P ¼ 0.537) and poor sleep
quality (60.0% vs. 61.7%; P ¼ 0.825) at baseline. However, they had
more frequently more advanced cancer stages at baseline (cancer
stage III: 14.2% vs. 29.2%; P ¼ 0.017).
Model-based clustering [21] was used to identify groups of pa-
tients that share similar time trends in the PSQI global score, while
distinguishing them from other groups of patients homogeneous
regarding the variation in sleep quality. According to this method,
the data are assumed to have a multivariate normal distribution,
parameterised by their mean and covariance, generated by clusters.
The geometric features (orientation, volume, and shape) of the
distribution are estimated from the data, and can be allowed to vary
between clusters, or constrained to be the same for all clusters [22].
The most appropriate model was considered allowing for the most
homogenous grouping of patients regarding their patterns of sleep
variation, as assessed by visual inspection, would be selected
among those with the lowest value of Bayesian Information
Criterion.
Sample characteristics are presented as counts and proportions
for categorical variables and median and P25eP75 for quantitative
variables with markedly asymmetrical distribution. The mean PSQI
score between the baseline and the one year follow-up evaluations
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were compared using the Student's' t test for paired samples, for
each of the trajectories identiﬁed.
Odds ratio (OR) and the corresponding 95% conﬁdence intervals
(95%CI) for the association between different characteristics of the
patients, including cancer treatments and neurological complica-
tions, and trajectories of sleep quality up to three years after breast
cancer diagnosis, were computed using multinomial logistic
regression. Variables included in each model are those known to be
associated with the exposure and outcome of interest, without
being an intermediate steep in this relation, as supported by sci-
entiﬁc literature, and are described as footnotes of Tables 1 and 2.
Statistical analysis were conducted using R, version 3.0.1 (R Core
Team, Vienna, Austria) and STATA®, version 11.2 (StataCorp, College
Station, TX, USA).Table 1
Adjusted odds ratio (OR) for the association between sociodemographic and clinical chara
trajectory as reference.
High sleep quality (HSQ) Medium sleep
N (%) N (%)
Age (years)
<55 44 (18.2) 123 (50.8)
55 29 (13.4) 121 (56.0)
Education (years)
4 25 (12.8) 103 (52.8)
5e9 23 (17.6) 68 (51.9)
10 25 (18.9) 73 (55.3)
Anxiety at baselineb [N ¼ 457a]
No 55 (19.7) 162 (58.1)
Yes 18 (10.1) 81 (45.5)
Depression at baselinec
No 72 (17.1) 232 (55.0)
Yes 1 (2.8) 12 (33.3)
Cognitive impairment at baseline
No 65 (15.5) 224 (53.3)
Yes 8 (21.0) 20 (52.6)
Menopausal status at baseline [N ¼ 441a]
Premenopausal 40 (21.0) 92 (48.4)
Postmenopausal 31 (12.4) 140 (55.8)
Cancer stage
0 (DCIS)/I 39 (15.5) 133 (52.8)
II 25 (17.7) 76 (53.9)
III 9 (13.8) 35 (52.8)
Breast surgeryd
Breast-conserving 40 (17.2) 118 (50.6)
Mastectomy 33 (14.7) 126 (56.0)
Axillary surgerye
None/SLNB 51 (16.6) 162 (52.6)
ALND 22 (14.7) 82 (54.7)
Chemotherapy
No 26 (14.0) 92 (49.5)
Yes 47 (17.3) 152 (55.9)
Radiotherapy (internal and/or external)
No 14 (14.2) 66 (55.0)
Yes 56 (16.6) 178 (52.7)
Endocrine therapy
No 10 (13.9) 42 (58.3)
Yes 63 (16.3) 202 (52.3)
Immunotherapy
No 61 (15.3) 211 (52.9)
Yes 12 (30.3) 33 (55.9)
ALND, Axillary lymph node dissection; DCIS, Ductal carcinoma in situ; OR, Odds radio; S
a N < 458 due to missing data.
b Deﬁned as a score greater than or equal to 11 in the anxiety subscale of the Hospita
c Deﬁned as a score greater than or equal to 11 in the depression subscale of the Hos
d Patients who had both mastectomy and breast-conserving surgery are reported as m
e Patients who had both ALND and SLNB are reported as ALND.
f Adjusted for age.
g Adjusted for age, education and cancer stage.
h Adjusted for age, education, cancer stage, anxiety at baseline, depression at baseline
i Adjusted for age and education.
j Adjusted for age, education, cancer stage, and breast and axillary surgery.
k Adjusted for age, education, cancer stage and menopausal status.2.4. Ethics
The study was approved by the Ethics Committee of the IPO-
Porto (CES 406/011, CES 99/014, and CES 290/014) and by the Por-
tuguese Data Protection Authority (Ref. 9469/2012 and Ref 8601/
2014). All participants provided written informed consent.
3. Results
At baseline, more than half of the women were less than 55
years of age (52.8%) and more than two thirds was less than 10
years of education (71.2%). Most of them were diagnosed with
cancer stage 0 or I (55.0%). A total of 84.3%, 73.1%, and 59.4%
received endocrine therapy, radiotherapy, and chemotherapy, in
addition to surgical treatment.cteristics of the patients and trajectories of sleep quality, using the high sleep quality
quality (MSQ) Low sleep quality (LSQ)
OR (95%CI) N (%) OR (95%CI)
1 (ref.) 75 (31.0) 1 (ref.)
1.49 (0.88e2.54) 66 (30.6) 1.34 (0.75e2.67)
1 (ref.) 67 (34.4) 1 (ref.)
0.82 (0.41e1.63)f 40 (30.5) 0.67 (0.32e1.40)f
0.81 (0.41e1.60)f 34 (27.8) 0.52 (0.25e1.10)f
1 (ref.) 62 (22.2) 1 (ref.)
1.56 (0.86e2.83)g 79 (44.4) 3.93 (2.09e7.39)g
1 (ref.) 118 (28.0) 1 (ref.)
3.69 (0.47e29.0)g 23 (63.9) 14.6 (1.9e110.9)g
1 (ref.) 131 (31.2) 1 (ref.)
0.82 (0.33e2.02)h 10 (26.3) 0.72 (0.25e2.08)h
1 (ref.) 58 (30.5) 1 (ref.)
2.53 (0.88e7.27)f 80 (31.9) 2.64 (0.87e7.98)f
1 (ref.) 80 (31.8) 1 (ref.)
0.67 (0.32e1.42)i 40 (28.4) 0.83 (0.43e1.58)i
0.53 (0.25e1.11)i 21 (32.3) 1.20 (0.50e2.91)i
1 (ref.) 75 (32.2) 1 (ref.)
1.33 (0.76e2.33)g 66 (29.3) 1.11 (0.60e2.02)g
1 (ref.) 95 (30.8) 1 (ref.)
1.35 (0.60e3.02)g 46 (30.7) 1.33 (0.55e3.20)g
1 (ref.) 68 (36.6) 1 (ref.)
0.98 (0.51e1.90)g 73 (26.8) 0.53 (0.26e1.10)g
1 (ref.) 37 (30.8) 1 (ref.)
1.00 (0.39e2.57)j 104 (30.8) 0.81 (0.29e2.26)j
1 (ref.) 20 (27.8) 1 (ref.)
0.97 (0.43e2.16)k 121 (31.4) 1.05 (0.44e2.52)k
1 (ref.) 127 (31.8) 1 (ref.)
0.82 (0.39e1.69)g 14 (23.7) 0.59 (0.25e1.36)g
LNB, Sentinel lymph node biopsy; 95%CI, 95% conﬁdence interval.
l Anxiety and Depression Scale.
pital Anxiety and Depression Scale.
astectomy.
, chemotherapy and endocrine therapy.
Table 2
Adjusted odds ratio (OR) for the association between neurological complications at one and three-years after cancer diagnosis and trajectories of sleep quality, using the high
sleep quality trajectory as reference.
High sleep quality (HSQ) Medium sleep quality (MSQ) Low sleep quality (LSQ)
N (%) N (%) OR (95%CI) N (%) OR (95%CI)
Neuropathic pain at one-year
No 64 (17.6) 188 (51.8) 1 (ref.) 111 (30.6) 1 (ref.)
Yes 9 (9.5) 56 (59.0) 2.01 (0.89e4.51)a 30 (31.6) 1.23 (0.51e2.99)a
Neuropathic pain at three-years
No 68 (19.4) 187 (53.4) 1 (ref.) 95 (27.1) 1 (ref.)
Yes 5 (4.6) 57 (52.8) 4.12 (1.55e10.94)a 46 (42.6) 5.49 (1.99e15.12)a
CIPN at one-year
No 66 (16.7) 209 (52.9) 1 (ref.) 120 (30.4) 1 (ref.)
Yes 7 (11.1) 35 (55.6) 1.68 (0.67e4.17)b 21 (33.3) 2.13 (0.79e5.79)b
CIPN at three-years
No 67 (14.5) 217 (53.3) 1 (ref.) 123 (30.2) 1 (ref.)
Yes 6 (11.8) 27 (52.9) 1.40 (0.53e3.71)b 18 (35.3) 2.05 (0.71e5.91)b
Cognitive impairment at one-year
No 68 (16.0) 227 (53.4) 1 (ref.) 130 (30.6) 1 (ref.)
Yes 5 (15.2) 17 (51.5) 1.11 (0.38e3.20)c 11 (33.3) 1.21 (0.37e3.89)c
Cognitive impairment at three-years
No 68 (16.2) 223 (53.0) 1 (ref.) 130 (30.9) 1 (ref.)
Yes 5 (13.5) 21 (56.8) 1.22 (0.44e3.41)c 11 (29.7) 0.87 (0.28e2.76)c
CIPN, Chemotherapy-induced peripheral neuropathy.
a Adjusted for age, education, cancer stage, anxiety at baseline, depression at baseline, chemotherapy, breast and axillary surgery and radiotherapy.
b Adjusted for age, education, cancer stage, anxiety at baseline, depression at baseline and chemotherapy.
c Adjusted for age, education, cancer stage, anxiety at baseline, depression at baseline, chemotherapy and endocrine therapy.
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quality over a period of three years after breast cancer diagnosis
were identiﬁed (Fig. 1). Trajectory 1 (141 patients) and trajectory 2
(244 patients), labelled as “low” (LSQ) and “medium sleep quality”
(MSQ), respectively, though presenting signiﬁcant differences be-
tween them, both are characterized by mean values of poor sleep
quality (PSQI global score >5) during the whole period. However,
while in the former there was an improvement in sleep quality
(P < 0.001), the latter is characterized by a deterioration in sleep
quality (P < 0.001) during the ﬁrst year. After the one-year follow-
up evaluation, there was a levelling-off in sleep quality in both
trajectories. Trajectory 3 (73 patients), labelled as “high sleep
quality” (HSQ) presents mean values of good sleep quality (PSQI
global score 5) and a stable trend in PSQI global score during the
whole follow-up.
The PSQI components scores in the three moments of evalua-
tion, according to the different trajectories of sleep quality, are
depicted in Fig. 2. The LSQ trajectory is characterized by higher
mean values of each PSQI components than those found in theFig. 1. Means and the corresponding 95% conﬁdence intervals of the Pittsburgh Sleep
Quality Index (PSQI) score for each trajectory identiﬁed. PSQI, Pittsburgh Sleep Quality
Index. Higher PSQI scores correspond to a worse sleep quality.remaining trajectories, in all the moments of follow-up, and by a
decrease in sleep latency and daytime dysfunction and by an in-
crease in sleep duration and habitual sleep efﬁciency, between
baseline and the one-year follow-up evaluation. The HSQ trajec-
tory presented the lowest mean scores in all PSQI components;
sleep disturbances were the major contributor to overall PSQI
score, with at least two-times higher values than other compo-
nents of the same trajectory. In the MSQ trajectory there was a
more similar distribution between PSQI components scores in the
three evaluations, and a decrease in habitual sleep efﬁciency and
an increase in the use of sleep medication between baseline and
the one-year follow-up evaluation.
Table 1 presents results for the association between socio-
demographic and clinical characteristics of patients and trajectories
of sleep quality. Anxiety and depression prior to the beginning of
treatments were signiﬁcantly more frequent among patients in LSQ
than in those in HSQ.
There were no statistically signiﬁcant differences between
treatments performed during the ﬁrst year of follow-up across the
different trajectories of sleep quality (Table 1). However, those in
the LSQ and in the MSQ trajectories were more likely to present NP
three years after cancer diagnosis (Table 2).
4. Discussion
Our study identiﬁed three main trajectories of variation in sleep
quality during three years after breast cancer diagnosis. Despite the
LSQ and theMSQ trajectories presented values of poor sleep quality
during the whole follow-up, the latter is characterized by a dete-
rioration in sleep quality and the former by an improvement in
sleep quality during the ﬁrst year. The HSQ trajectory is charac-
terized by good sleep quality during the whole period. Patients
included in the LSQ trajectory were more likely to present anxiety
and depression prior to treatments. The two trajectories with poor
sleep quality over time presented more frequently NP three years
after cancer diagnosis.
To our knowledge, only one previous study identiﬁed subgroups
of breast cancer patients based on changes in sleep quality over
time, using a model-based approach [23]. Using growth mixture
Fig. 2. Pittsburgh Sleep Quality Index (PSQI) components scores in the three moments of evaluation, according to each trajectory identiﬁed. PSQI, Pittsburgh Sleep Quality Index.
Higher scores of PSQI components (range: 0e3) correspond to worse outcomes, e.g. lower subjective sleep quality, higher sleep latency, less sleep duration, less habitual sleep
efﬁciency, higher sleep disturbances, higher use of sleep medication and higher daytime dysfunction.
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disturbance trajectories in a sample of approximately 400 women
enrolled prior to surgery and followed during six months; their
study yielded a “high sustained class” and a “low sustained class”
that had high and low levels of sleep disturbance prior to surgery
that persisted for six months, respectively, and a “decreasing class”
that had high levels of sleep disturbance prior to surgery that
decreased over time, although the latter was identiﬁed in only 21
patients [23]. Despite direct comparisons between the two studies
are hampered by the use of different methods to evaluate sleep
quality and to summarize the trends, and by the use of different
follow-up periods and moments of sleep assessment, both studies
identiﬁed one trajectory with levels of good sleep quality constant
over time and another one with a trend toward better sleep quality
during the ﬁrst year. The longer follow-up of our analysis adds to
previous research the identiﬁcation of trajectories during a period
of three years.
Other prospective studies have evaluated sleep quality in breast
cancer patients in different periods after cancer diagnosis [24,25].
In a study assessing women scheduled to receive neoadjuvant or
adjuvant chemotherapy for breast cancer, Ancoli-Israel et al.
showed that compared to non-cancer controls breast cancer pa-
tients had signiﬁcantly worse scores for sleep quality, fatigue,
depressive symptoms and quality of life, at baseline, during
chemotherapy and after one year; among breast cancer patients,
sleep quality returned to baseline levels at one year [24]. Using data
from the same cohort of patients, Liu et al. reported that breast
cancer patients with a higher pre-treatment symptom cluster index
(worse sleep, more fatigue and more depressive symptoms) were
also more symptomatic during chemotherapy, when compared to
those with fewer symptoms before treatment [25]. Despite meth-
odological differences, our ﬁndings are in accordance with the
previous results, since in our study the patients' sleep quality tra-
jectory was largely inﬂuence by sleep quality at baseline and therewas a statistically signiﬁcant relation between sleep quality over
time and the presence of anxiety and depression at baseline.
Psychiatric disorders have been described as predisposing fac-
tors for insomnia in the general population [26] and in breast
cancer patients [2,27]. On the other hand, insomnia symptoms are
among the diagnostic criteria and risk factors for several psychiatric
disorders [28]. Although it was not surprising to ﬁnd a higher fre-
quency of anxiety and depression in trajectories with worse sleep
quality prior to treatments and over time, our strategy of data
analysis precludes the assumption of a direction for the association
between anxiety and depression, and sleep quality. The trend to-
ward an improvement in sleep quality during the ﬁrst year of
follow-up, among those in the LSQ trajectory, may be explained by
the treatment of some of the patients with greater scores of anxiety
and depression prior to treatments, and its subsequent impact on
sleep quality one year after enrolment. Unfortunately, the absence
of data regarding pharmacological treatments for anxiety and
depression, at baseline and during the follow-up, did not allow us
to test this hypothesis.
Although not statistically signiﬁcant, there was a higher pro-
portion of postmenopausal women in trajectories with poor sleep
quality at baseline. This is consistent with previous knowledge that
menopausal vasomotor symptoms (including hot ﬂashes) are
associated with disrupted sleep [27,29]. However, a study that
evaluated the effect of menopausal symptoms on sleep quality in
breast cancer patients, using both objective and subjective mea-
sures, found that women who were premenopausal before and
after chemotherapy had worse sleep than those who were either
premenopausal prior to chemotherapy and became perimeno-
pausal after chemotherapy or were postmenopausal [30]; the au-
thors hypothesized that other physical or psychological variables
not evaluated in their study, such as the prior exposure to meno-
pausal symptoms, could have contributed to their results [30]. In
our study, the absence of data regarding the potential modiﬁcation
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during treatments trajectory, either naturally or as a consequence
of cancer treatment, did not allow us to infer about the role of this
variable on the change of sleep quality pattern, mainly during the
ﬁrst year of follow-up.
Previous studies have supported the strong relation between
fatigue and sleep, reporting that the two symptoms often co-occur
with depression as part of a symptom cluster in breast cancer pa-
tients [31,32]. Ho et al. investigated the relation between the three
symptoms showing moderate to strong associations, prior to and
following chemotherapy for breast cancer [31]. In another study,
Berger et al. examined patterns of circadian rhythms and their
relationship with fatigue, anxiety and depression, and concluded
that disrupted patterns of circadian rhythms were associated with
distressing fatigue and depressive symptoms during chemotherapy
and at recovery [32]. Therefore, although fatigue was not evaluated
in the present study, it may have also contributed to the sleep
trajectories among these patients.
NP is a frequent complication of both surgical and adjuvant
treatments for breast cancer [33,34]. In or study, both the LSQ and
the MSQ trajectories, were more likely to include patients with NP
at the three-year follow-up. It has been described that the context
in which a painful stimulus occurs affects how patients perceive it
and that psychological factors such as depression, somatization,
poor coping skills, and social stressors can predict the development
of chronic pain [35]. In addition, in a previous analysis of data from
the same cohort of patients, we described that NP was less severe
among women presenting this condition at the one-year follow-up
evaluation than those with NP three years after cancer diagnosis
[13], which could at least in part, explain the absence of statistically
signiﬁcant differences in the proportion of NP at one-year across
different trajectories.
The major strengths of our study are the longitudinal analysis
of sleep quality, with an evaluation prior to treatments and the
much longer follow-up than the previous study analysing sub-
groups of breast cancer patients based on changes in sleep quality
over time. However, some limitations need to be acknowledged.
As we did not evaluate sleep quality before cancer diagnosis, the
proportion of patients for which poor sleep quality is a conse-
quence of the diagnosis of an oncological disease is unknown.
Also, the assessment of a cohort with a large number of partici-
pants precludes the use of objective measures of sleep to
corroborate the patients' self-reports. Nevertheless, PSQI is one of
the measures recommended to assess sleep or insomnia symp-
toms in epidemiological studies and has demonstrated good
psychometric properties [36]. Finally, NP and the remaining
neurological complications had only clinical diagnosis, which may
limit the accuracy of the information regarding these disorders.
Nevertheless, our results reﬂect ﬁndings in usual clinical practice,
since all patients were treated according to the usual practice of a
major oncological hospital.
5. Conclusions
The present study provides a model for describing the variation
in sleep quality during three years after cancer diagnosis, based in
three main trajectories. Our results show that a high proportion of
women already presented poor sleep quality prior to treatments,
which persisted during three years. In addition, there was a relation
between trajectories of worse sleep quality during this period and
psychiatric disorders at baseline and NP at three years. These re-
sults emphasize the importance of monitoring sleep quality prior to
the onset of cancer treatment, and reinforce the necessity of
management of comorbidities for a comprehensive treatment of
sleep disorders among breast cancer patients. Further studies areneeded to understand the heterogeneity of the individual trajec-
tories within each of these major patterns of variation, and their
associated factors.Funding
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